418 results on '"Cheng, Gregory"'
Search Results
52. Increase in Incidence of Hepatocellular Carcinoma in Chronic Hepatitis C Chinese After Sustained Virologic Response with Direct Acting Antiviral Agents as Compared to Pegylated Interferon Plus Ribavirin Therapy: A Prospective Open-Label Study
53. Eltrombopag Plus Pulsed Dexamethasone As First Line Therapy for Subjects with Immune Thrombocytopenic Purpura (ITP)
54. Effects of atrioventricular asynchrony on platelet activation: implication of thromboembolism in paced patients
55. Vitamin B12 deficiency—need for a new guideline
56. To err is human nature. Can transfusion errors due to human factors ever be eliminated?
57. Population-Wide Genetic Risk Prediction of Complex Diseases: A Pilot Feasibility Study in Macau Population for Precision Public Healthcare Planning
58. Scalable Generation of Mesenchymal Stem Cells from Human Embryonic Stem Cells in 3D
59. A novel green gelatin–agar microencapsulation system with P. urinaria as an improved anti-A. niger model
60. Preparation of Galipea officinalis Hancock type tetrahydroquinoline alkaloid analogues as anti-tumour agents
61. Development of hydrocortisone succinic acid/and 5-fluorouracil/chitosan microcapsules for oral and topical drug deliveries
62. Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
63. Vemurafenib As First Treatment of Hairy Cell Leukemia
64. Synthesis, characterization and preliminary analysis of in vivo biological activity of chitosan/celecoxib microcapsules
65. The preparation of bi-functional organophosphine oxides as potential antitumor agents
66. Corrigendum to “Development of hydrocortisone succinic acid/and 5-fluorouracil/chitosan microcapsules for oral and topical drug deliveries” [Bioorg. Med. Chem. Lett. 22 (2012) 3213–3218]
67. Preparation and characterization of bio-safe activated charcoal derived from coffee waste residue and its application for removal of lead and copper ions
68. Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy
69. The preparation and in vitro antiproliferative activity of phthalimide based ketones on MDAMB-231 and SKHep-1 human carcinoma cell lines
70. The preparation of 2,6-disubstituted pyridinyl phosphine oxides as novel anti-cancer agents
71. Long-Term Safety and Efficacy of Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP): Report of up to 5.5 Years of Treatment in EXTEND.
72. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile
73. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
74. Thrombophilia among Chinese Women with Venous Thromboembolism during Pregnancy
75. Development of Calendula Oil/Chitosan Microcapsules and their Biological Safety Evaluation
76. Development of formaldehyde-free agar/gelatin microcapsules containing berberine HCl and gallic acid and their topical and oral applications
77. Safety and Efficacy of Extended Treatment with Eltrombopag in Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2011,
78. Eltrombopag for chronic immune thrombocytopenia – Authors' reply
79. Incidence of Deep Vein Thrombosis in Hospitalized Chinese Medical Patients and the Impact of DVT Prophylaxis
80. Incidence of Thromboembolic Events Across Eltrombopag Clinical Trials In Chronic Immune Thrombocytopenia (ITP)
81. EXTEND Study Update: Safety and Efficacy of Eltrombopag In Adults with Chronic Immune Thrombocytopenia (ITP) From June 2006 to February 2010
82. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients
83. Synthesis of 9,9‐Dialkyl‐4,5‐diazafluorene Derivatives and Their Structure–Activity Relationships Toward Human Carcinoma Cell Lines
84. Novel Use of Silymarin as Delayed Therapy for Acetaminophen-Induced Acute Hepatic Injury
85. Time to Splenectomy Failure in Patients with Recurrent or Refractory Chronic Immune Thrombocytopenic Purpura.
86. Evaluation of Hepatobiliary Parameters During Eltrombopag Treatment in Patients with Chronic Immune Thrombocytopenic Purpura.
87. Platelet Counts Following Eltrombopag Discontinuation in Patients with Chronic Immune Thrombocytopenic Purpura.
88. Long-Term Treatment of Chronic Immune Thrombocytopenic Purpura with Oral Eltrombopag: Results From the EXTEND Study.
89. Thromboembolic Events Observed in Eltrombopag Clinical Trials in Chronic Immune Thrombocytopenic Purpura.
90. Synthesis and structure evaluation of a novel cantharimide and its cytotoxicity on SK-Hep-1 hepatoma cells
91. Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/μL - Data from the EXTEND Study.
92. Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study
93. Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura.
94. Oral Eltrombopag Treatment Reduces the Need for Concomitant Medications in Patients with Chronic Idiopathic Thrombocytopenic Purpura.
95. Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE)
96. W1019 Effects of Eltrombopag On Thrombopietin Levels During Antiviral Therapy in HCV Patients with Cirrhosis
97. Synthesis and Characterization of Some Metal Complexes of 4,5-Diazafluoren-9-one and their Biological Effects on Human Carcinoma Cells
98. Platelet Counts Remain Elevated in Two Patients with Idiopathic Thrombocytopenic Purpura after Cessation of Oral Eltrombopag.
99. Long-Term Safety and Efficacy of Oral Eltrombopag for the Treatment of Subjects with Idiopathic Thrombocytopenic Purpura (ITP): Preliminary Data from the EXTEND Study.
100. Paradoxical proliferative potential of iron (II) sulphate on cancer cells after the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.